AI Pathology Test Outperforms Oncotype DX Gold Standard in HR+/HER2- Patients

kjgeras · x · 2026-07-06

In HR+/HER2- patients (n=858), this AI pathology test was directly compared against the 20-year clinical gold standard Oncotype DX (21-gene assay). It achieved a C-index of 0.67 vs. 0.61 and outperformed Oncotype DX across multiple thresholds in decision curve analysis.

Related event: Multimodal AI Pathology Test Outperforms Gold Standard in Breast Cancer Recurrence Prediction(11 posts)→

Original post →

More from Research

Research channel →